Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

About this update from Clearmind Medicine Inc.

Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated mental health problems, with a focus on Alcohol Use Disorder and other addiction related diagnoses, today announced that it has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) about MEAI's potential as an innovative, empirically-evidenced intervention for the treatment of addiction. Clearmind proposes an innovative model to enable inexpensive, scalable, and clinically effective treatment for Americans living with alcohol use disorder (AUD). The Clearmind approach places a focus on FDA-regulated research and development of an emerging class of pharmaceutical agents, non-hallucinogenic neuroplastogens, which promote the neuroplasticity provided by classic psychedelics but without hallucinogenic and the need for hours of costly supervised dosing. In its submission, Clearmind highlights its proprietary MEAI-based candidate CMND-100, an innovative non-hallucinogenic neuroplastogen for AUD and binge behaviors. The document emphasizes that AUD affects approximately 10% of the U.S. population , with only 1 in 10 Americans receiving treatment , and positions MEAI as a potentially leading intervention that may meet many objectives of the U.S. Administration, including through MEAI's scalable, at-home solution with low abuse potential that is designed to engage neural pathways, such as 5-HT1A, to support moderation and long-term recovery "Clearmind's submission to the HHS RFI underscores our commitment to supporting the Great American Recovery Initiative with science-driven, non-opioid solutions for addiction," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. "We believe that CMND-100 represents a promising new approach that could help millions struggling with alcohol use disorder and binge behaviors. We are proud to contribute our clinical insights and data to this important national effort aimed at enhancing prevention, treatment, and long-term recovery. We are grateful that President Trump and Secretary Kennedy are looking to transform addiction treatment through the expansion of new therapeutic approaches, and our research at Yale and Johns Hopkins indicates that MEAI is well-positioned to lead in these efforts." This RFI is part of the Administration's Great American Recovery Initiative . It invites researchers, companies, healthcare providers and the public to submit comments, successful programs, and novel policy ideas aimed at improving prevention, treatment, and recovery from addiction and co-occurring mental health conditions, using existing federal resources.

View stock analysis, news, and events for Clearmind Medicine Inc.